An Activist Investor Keeps Buying Gerresheimer Stock — But Can It Fix a Company Still Wrestling With Accounting Scandals and Crushing Debt?
Shares of Gerresheimer are surging. The German pharma-packaging maker has rallied +9% in six sessions to €27.34, after Luxembourg-based Active Ownership Fund disclosed it raised its stake to 15.19% from 14.70% — its latest in a string of aggressive purchases since first appearing on the register last August. The move signals a deepening activist bet on a company whose stock has lost roughly 80% from its 2023 peak, but the turnaround thesis is far from risk-free.
• The Activist Has a Board Ally and a Clear Playbook. Klaus Röhrig, a member of Gerresheimer's supervisory board, is closely affiliated with the Active Ownership Fund.
The investor is urging a quick sale of the moulded glass unit, saying it would cut debt and boost cash flow.
It has also called on Gerresheimer to streamline operations, claiming such measures could lift the company's profit margin by around five percentage points. That kind of inside access gives the fund real leverage to push change — but execution is another matter entirely.
• The Books Remain a Black Box. Germany's financial regulator BaFin accused the company of accounting errors; an independent law firm found that revenues had been "systematically recognized too early."
Internal investigations forced a postponement of the 2025 annual financials, which Gerresheimer now aims to publish in June 2026. Until the audit comes back clean, every rally trades on faith, not facts.
• Lenders Are Buying Time, Not Confidence. Some 96% of holders of €870 million in promissory notes agreed to extend the filing deadline to September 30, 2026, and key debt-ratio covenants have been waived through Q3.
Analysts at Bernstein warned that covenant renegotiation costs could run €10–20 million above the original €100 million estimate. The company's net debt sits near €1.2 billion — roughly 4x operating profit — and it is selling its profitable U.S. subsidiary Centor to lighten the load.
• A Rejected €41-Per-Share Bid Raises the Stakes. Gerresheimer turned down a takeover approach from U.S.-based Silgan , which valued the company at roughly €41 per share — more than twice the current price. Management says it wants to fix accounting issues first. If the cleanup succeeds, today's €27 price could look like a bargain. If it doesn't, rejecting that bid may prove costly.